Sector ratings Celltrion, Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 06/09/2024			5-day change	1st Jan Change
191,200.00 ^KRW	+1.70%		-5.81%	-5.11%

08-29	Celltrion Usa Partners with Express Scripts and Cigna Healthcare to Expand Access to Zymfentra® (Infliximab-Dyyb), the First and Only Fda-Approved Subcutaneous Infliximab on Their Medical Benefit Formulary	CI
08-26	European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases	CI

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	ESG Refinitiv	Capi. ($)
CELLTRION, INC.		C	29.63B
LONZA GROUP AG		A	46.02B
IQVIA HOLDINGS INC.		B	44.31B
ALNYLAM PHARMACEUTICALS, INC.	-	B	31.68B
MODERNA, INC.	-	B-	28.02B
ICON PUBLIC LIMITED COMPANY		B-	25.05B
UNITED THERAPEUTICS CORPORATION		B+	15.38B
BIO-TECHNE CORPORATION		B+	11.34B
MEDPACE HOLDINGS, INC.		C+	10.39B
QIAGEN N.V.		A	9.89B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.		C+	9.7B
REVOLUTION MEDICINES, INC.	-	C-	6.99B
IONIS PHARMACEUTICALS, INC.	-	B+	6.86B
BACHEM HOLDING AG		B-	6.7B
HANGZHOU TIGERMED CONSULTING CO., LTD		B+	5.51B
BLUEPRINT MEDICINES CORPORATION		B-	5.47B
ALKERMES PLC		B	4.42B
Average		B	17.49B
Weighted average by Cap.		B